Glial Tumor Grading and Outcome Prediction Using Dynamic Spin-Echo MR Susceptibility Mapping Compared with Conventional Contrast-Enhanced MR: Confounding Effect of Elevated rCBV of Oligodendroglimoas

References

1. ↵
   Kleihues P, Burger PC, Scheithauer BW. Histological Typing of Tumors of the Central Nervous System, 2nd ed. Berlin: Springer-Verlag;1993
2. ↵
   Dumas-Duport C, Scheithauer B, O’Fallon J, et al. Grading of astrocytomas: a simple and reproducible method. Cancer 1988;62:2152–2165

   CrossRefPubMedWeb of Science
3. ↵
   Scatliff JH, Radcliffe WB, Pittman HH, Park CH. Vascular structure of glioblastomas. Radium Ther Nucl Med 1969;105:795–805
4. Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 1972;48:347–356
5. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996;77:362–372

   CrossRefPubMedWeb of Science
6. Assimakopoulou M, Sotiropoulou-Bonikou G, Maraziotis T, Papadakis N, Varakis. Microvessel density in brain tumors. Anticancer Res 1997;17:4747–4753

   PubMed
7. ↵
   Abdulrauf SI, Edvardsen K, Ho KL, Yang XY, Rock JP, Rosenblum ML. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 1998;88:513–520

   PubMedWeb of Science
8. ↵
   Barker FG II, Chang SM, Huhn SL, et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 1997;80:936–941

   CrossRefPubMed
9. Wong JC, Provenzale JM, Petrella JR. Perfusion MR imaging of brain neoplasms. AJR Am J Roentgenol 2000;174:1147–1157

   PubMed
10. ↵
    Sugahara T, Korogi Y, Shigematsu Y, et al. Value of dynamic susceptibility contrast magnetic resonance imaging in the evaluation of intracranial tumors. Top Magn Reson Imaging 1999;10:114–124

    PubMed
11. ↵
    Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41–51

    PubMedWeb of Science
12. ↵
    Donahue KM, Krouwer HG, Rand SD, et al. Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med 2000;43:845–853

    CrossRefPubMedWeb of Science
13. ↵
    Aronen HJ, Glass J, Pardo FS, et al. Echo-planar MR cerebral blood volume mapping of gliomas: clinical utility. Acta Radiol 1995;36:520–528

    PubMed
14. ↵
    Lev MH, Rosen BR. Clinical applications of intracranial perfusion MR imaging. Neuroimaging Clin N Am 1999;9:309–331

    PubMedWeb of Science
15. ↵
    Sugahara T, Korogi Y, Kochi M, Ushio Y, Takahashi M. Perfusion-sensitive MR imaging of gliomas: comparison between gradient-echo and spin-echo echo-planar imaging techniques. AJNR Am J Neuroradiol 2001;22:1306–1315

    Abstract/FREE Full Text
16. Fisel CR, Ackerman JL, Buxton RB, et al. MR contrast due to microscopically heterogeneous magnetic susceptibility: numerical simulations and applications to cerebral physiology. Magn Reson Med 1991;17:336–347

    PubMedWeb of Science
17. Ogawa S, Menon RS, Tank DW, et al. Functional brain mapping by blood oxygenation level-dependent contrast magnetic resonance imaging: a comparison of signal characteristics with a biophysical model. Biophys J 1993;64:803–812

    CrossRefPubMedWeb of Science
18. ↵
    Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM. MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 1995;34:555–566

    CrossRefPubMedWeb of Science
19. ↵
    Knopp EA, Cha S, Johnson G. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211:791–798

    CrossRefPubMedWeb of Science
20. ↵
    Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998;171:1479–1486

    CrossRefPubMedWeb of Science
21. ↵
    Derlon JM, Chapon F, Noel MH, et al. Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med 2000;27:778–787

    CrossRefPubMedWeb of Science
22. Bader JB, Samnick S, Moringlane JR, et al. Evaluation of l-3-[123I] iodo-alpha-methyltyrosine SPECT and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy. Eur J Nucl Med 1999;26:144–151

    CrossRefPubMed
23. Viader F, Derlon JM, Petit-Taboue MC, et al. Recurrent oligodendroglioma diagnosed with 11C-L-methionine and PET: a case report. Eur Neurol 1993;33:248–251

    PubMed
24. ↵
    Sugou N, Shibata I, Nemoto A, et al. High uptake of N-isopropyl-p-[123I]-iodoamphetamine (123I-IMP) demonstrated by dynamic SPECT in some cases of glioma. Kaku Igaku 1996;33:695–704

    PubMed
25. ↵
    Weisskoff R, Rosen BR. Functional magnetic resonance imaging. Acad Radiol 1995;2:133–135
26. ↵
    Weisskoff RM, Rosen BR. Noninvasive determination of regional cerebral blood flow in rats using dynamic imaging with Gd(DTPA). Magn Reson Med 1992;25:211–223

    CrossRefPubMed
27. ↵
    Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995;195:47–52

    PubMed
28. Kelly PJ. Stereotatic histologic correlations of computed tomography and magnetic resonance imaging defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987;62:450–459

    CrossRefPubMedWeb of Science